Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2026)

Treace Medical Concepts has reported Cash & Equivalents for 7 years, with the latest figure at $9.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 28.63% year-over-year to $9.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.5 million (down 28.63% YoY), and the FY2025 full-year result was $10.7 million, down 5.66% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $9.5 million, down from $10.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $101.5 million in Q2 2022, with the low at $7.3 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $23.9 million across 5 years, with a median of $12.1 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 507.25% — and 2023, when it sank 88.15%.
• Treace Medical Concepts' Cash & Equivalents stood at $19.5 million in 2022, then plunged by 33.33% to $13.0 million in 2023, then decreased by 12.57% to $11.4 million in 2024, then dropped by 5.66% to $10.7 million in 2025, then slipped by 10.87% to $9.5 million in 2026.
• The last three Cash & Equivalents figures came in at $9.5 million (Q1 2026), $10.7 million (Q4 2025), and $7.7 million (Q3 2025), per Business Quant data.